BIOMAT Database Logo BIOMAT Database Logo

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. 1994

R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
National Institutes of Health, Bethesda, MD 20892.

A randomized pilot study comparing alternating and simultaneous regimens of zidovudine and didanosine (ddl) was conducted in 41 patients with AIDS or symptomatic human immunodeficiency virus (HIV) infection. Patients on each regimen received the same overall amounts of zidovudine and didanosine over time. CD4 cell counts in patients on the simultaneous regimen reached a maximum (mean +/- SE) of 108 +/- 16/mm3 above baseline (two-tailed P < or = .0001) and were significantly higher than in patients on the alternating regimen at all time points during weeks 6-45. At 54 weeks, the CD4 cell counts in the patients on the simultaneous regimen were still 40 +/- 19/mm3 above baseline. Patients on the simultaneous regimen also had significantly greater weight gain. While toxicities were generally mild and comparable between the regimens, 1 patient on the simultaneous regimen died of pancreatitis and lactic acidosis. Thus, simultaneous therapy provided more sustained elevations in CD4 cells than alternating therapy over 1 year and may be worth exploring in larger controlled trials.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010195 Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis. Acute Edematous Pancreatitis,Acute Pancreatitis,Pancreatic Parenchyma with Edema,Pancreatic Parenchymal Edema,Pancreatitis, Acute,Pancreatitis, Acute Edematous,Peripancreatic Fat Necrosis,Acute Edematous Pancreatitides,Acute Pancreatitides,Edema, Pancreatic Parenchymal,Edematous Pancreatitides, Acute,Edematous Pancreatitis, Acute,Fat Necrosis, Peripancreatic,Necrosis, Peripancreatic Fat,Pancreatic Parenchymal Edemas,Pancreatitides, Acute,Pancreatitides, Acute Edematous,Parenchymal Edema, Pancreatic,Peripancreatic Fat Necroses
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
May 1995, The Journal of infectious diseases,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Continued zidovudine or didanosine for human immunodeficiency virus infection.
November 1992, The New England journal of medicine,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Continued zidovudine or didanosine for human immunodeficiency virus infection.
November 1992, The New England journal of medicine,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Continued zidovudine or didanosine for human immunodeficiency virus infection.
November 1992, The New England journal of medicine,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection.
February 1994, Pediatrics,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
February 1997, The Journal of infectious diseases,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection.
November 1990, The Journal of pediatrics,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
February 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
February 2001, AIDS research and human retroviruses,
R Yarchoan, and J A Lietzau, and B Y Nguyen, and O W Brawley, and J M Pluda, and M W Saville, and K M Wyvill, and S M Steinberg, and R Agbaria, and H Mitsuya
Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virus.
February 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!